Monte Rosa's AI-Driven Discovery Platform Breaks Ground in Molecular Glue Degrader Research

Monte Rosa Therapeutics has published research in Science magazine showcasing its AI/ML-powered QuEEN™ discovery engine's ability to identify new methods to target proteins through cereblon (CRBN)-based degradation. The QuEEN™ engine has identified potential targets across over 100 previously undruggable protein classes, significantly broadening the therapeutic landscape in immunology, inflammation, and oncology. This positions Monte Rosa at the forefront of molecular glue degrader technology and has the potential to revolutionize drug design.